Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998, 90 (18): 1371-1388. 10.1093/jnci/90.18.1371.
Article
CAS
PubMed
Google Scholar
Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M: Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol. 2011, 29 (13): 1657-1663. 10.1200/JCO.2010.32.2933.
Article
PubMed
Google Scholar
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska , Kwan WH, Matthew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013, 381 (9869): 805-816. 10.1016/S0140-6736(12)61963-1.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S: Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol. 2003, 180 (1): 129-134. 10.2214/ajr.180.1.1800129.
Article
PubMed
Google Scholar
Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S: Tamoxifen-induced fatty liver in patients with breast cancer. Lancet. 1998, 351 (9104): 725-
Article
CAS
PubMed
Google Scholar
Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG: Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord. 2001, 25 (2): 296-298. 10.1038/sj.ijo.0801488.
Article
CAS
PubMed
Google Scholar
Cohen JC, Horton JD, Hobbs HH: Human fatty liver disease: old questions and new insights. Science. 2011, 332 (6037): 1519-1523. 10.1126/science.1204265.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U: Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005, 330 (7497): 932-10.1136/bmj.38391.663287.E0.
Article
PubMed
PubMed Central
Google Scholar
Cardoso CM, Custodio JB, Almeida LM, Moreno AJ: Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol. 2001, 176 (3): 145-152. 10.1006/taap.2001.9265.
Article
CAS
PubMed
Google Scholar
Lelliott CJ, Lopez M, Curtis RK, Parker N, Laudes M, Yeo G, Jimenez-Linan M, Grosse J, Saha AK, Wiggins D, Hauton D, Brand MD, O’Rahilly S, Griffin JL, Gibbons GF, Vidal-Puig A: Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J. 2005, 19 (9): 1108-1119. 10.1096/fj.04-3196com.
Article
CAS
PubMed
Google Scholar
Larosche I, Letteron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, Pessayre D, Mansouri A: Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther. 2007, 321 (2): 526-535. 10.1124/jpet.106.114546.
Article
CAS
PubMed
Google Scholar
Gudbrandsen OA, Rost TH, Berge RK: Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J Lipid Res. 2006, 47 (10): 2223-2232. 10.1194/jlr.M600148-JLR200.
Article
CAS
PubMed
Google Scholar
Lebrecht D, Vargas-Infante YA, Setzer B, Kirschner J, Walker UA: Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology. 2007, 45 (1): 72-79. 10.1002/hep.21490.
Article
CAS
PubMed
Google Scholar
Le TT, Urasaki Y, Pizzorno G: Uridine prevents fenofibrate-induced fatty liver. PLoS One. 2014, 9 (1): e87179-10.1371/journal.pone.0087179.
Article
PubMed
PubMed Central
Google Scholar
Connolly GP, Duley JA: Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci. 1999, 20 (5): 218-225. 10.1016/S0165-6147(99)01298-5.
Article
CAS
PubMed
Google Scholar
Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, Handschumacher RE: Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta. 2002, 1587 (2–3): 133-144.
Article
CAS
PubMed
Google Scholar
Cao D, Leffert JJ, McCabe J, Kim B, Pizzorno G: Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem. 2005, 280 (22): 21169-21175. 10.1074/jbc.M412343200.
Article
CAS
PubMed
Google Scholar
Le TT, Ziemba A, Urasaki Y, Hayes E, Brotman S, Pizzorno G: Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation. J Lipid Res. 2013, 54 (4): 1044-1057. 10.1194/jlr.M034249.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gasser T, Moyer JD, Handschumacher RE: Novel single-pass exchange of circulating uridine in rat liver. Science. 1981, 213 (4509): 777-778. 10.1126/science.7256279.
Article
CAS
PubMed
Google Scholar
Urasaki Y, Johlfs MG, Fiscus RR, Le TT: Imaging immune and metabolic cells of visceral adipose tissues with multimodal nonlinear optical microscopy. PLoS One. 2012, 7 (6): e38418-10.1371/journal.pone.0038418.
Article
CAS
PubMed
PubMed Central
Google Scholar
Le TT, Ziemba A, Urasaki Y, Brotman S, Pizzorno G: Label-free evaluation of hepatic microvesicular steatosis with multimodal coherent anti-stokes Raman scattering microscopy. PLoS One. 2012, 7 (11): e51092-10.1371/journal.pone.0051092.
Article
CAS
PubMed
PubMed Central
Google Scholar
Evans CL, Xie XS: Coherent anti-Stokes Raman scattering microscopy: chemically selective imaging for biology and medicine. Annu Rev Anal Chem. 2008, 1 (1): 883-909. 10.1146/annurev.anchem.1.031207.112754.
Article
CAS
Google Scholar
Le TT, Yue S, Cheng JX: Shedding new light on lipid biology with coherent anti-Stokes Raman scattering microscopy. J Lipid Res. 2010, 51 (11): 3091-3102. 10.1194/jlr.R008730.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang J, Nuebel E, Wisidagama DR, Setoguchi K, Hong JS, Van Horn CM, Imam SS, Vergnes L, Malone CS, Koehler CM, Teitell MA: Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. Nat Protoc. 2012, 7 (6): 1068-1085. 10.1038/nprot.2012.048.
Article
CAS
PubMed
Google Scholar
Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos. 1991, 19 (1): 36-43.
CAS
PubMed
Google Scholar
Pezacki JP, Blake JA, Danielson DC, Kennedy DC, Lyn RK, Singaravelu R: Chemical contrast for imaging living systems: molecular vibrations drive CARS microscopy. Nat Chem Biol. 2011, 7 (3): 137-145. 10.1038/nchembio.525.
Article
CAS
PubMed
Google Scholar
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005, 41 (6): 1313-1321. 10.1002/hep.20701.
Article
PubMed
Google Scholar
Garcia Urena MA, Colina Ruiz-Delgado F, Moreno Gonzalez E, Jimenez Romero C, Garcia Garcia I, Loinzaz Segurola C, Gonzalez P, Gomez Sanz R: Hepatic steatosis in liver transplant donors: common feature of donor population?. World J Surg. 1998, 22 (8): 837-844. 10.1007/s002689900479.
Article
CAS
PubMed
Google Scholar
Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, Shaw BW: Frozen section evaluation of donor livers before transplantation. Transplantation. 1993, 56 (6): 1403-1409. 10.1097/00007890-199312000-00025.
Article
CAS
PubMed
Google Scholar
El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, Puhan MA, Slankamenac K, Graf R, Clavien PA: Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg. 2009, 250 (5): 691-697. 10.1097/SLA.0b013e3181bcd6dd.
Article
PubMed
Google Scholar
Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, Watson PA, Birdsey N, Bao J, Gius D, Sack MN, Jing E, Kahn CR, Friedman JE, Jonscher KR: Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J. 2011, 433 (3): 505-514. 10.1042/BJ20100791.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, Stancakova A, Goetzman E, Lam MM, Schwer B, Stevens RD, Muehlbauer MJ, Kakar S, Bass NM, Kuusisto J, Laakso M, Alt FW, Newgard CB, Farese RV, Kahn CR, Verdin E: SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011, 44 (2): 177-190. 10.1016/j.molcel.2011.07.019.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kent C: Eukaryotic phospholipid biosynthesis. Annu Rev Biochem. 1995, 64: 315-343. 10.1146/annurev.bi.64.070195.001531.
Article
CAS
PubMed
Google Scholar
Cao D, Ziemba A, McCabe J, Yan R, Wan L, Kim B, Gach M, Flynn S, Pizzorno G: Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. Mol Cancer Ther. 2011, 10 (12): 2330-2339. 10.1158/1535-7163.MCT-11-0202.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cai J, Lee CW: Tamoxifen inhibits nitrobenzylthioinosine-sensitive equilibrative uridine transport in human MCF-7 breast cancer cells. Biochem J. 1996, 320 (Pt 3): 991-995.
Article
CAS
PubMed
PubMed Central
Google Scholar
Traut TW, Jones ME: Uracil metabolism–UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Prog Nucleic Acid Res Mol Biol. 1996, 53: 1-78.
Article
CAS
PubMed
Google Scholar
Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P: Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res. 1998, 4 (5): 1165-1175.
CAS
PubMed
Google Scholar